Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Uran Boom: Die Bullen starten durch - spektakuläre Kursgewinne möglich
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
38 Leser
Artikel bewerten:
(0)

A Simple Clinical Tool to Identify a Patient's Risk of Skipping Medications after Liver Transplantation

WASHINGTON, Nov. 2, 2013 /PRNewswire/ --Researchers at Northwestern University and Emory University propose a simple tool to identify patients who are at risk of engaging in "medication tradeoffs." The study authors address the problem of patients with financial hardship who make the regular choice of meeting basic needs such as buying food rather than paying for medications after receiving a liver transplant.

Researchers conducted detailed, in-person interviews with 105 patients at the two transplant centers who underwent liver transplantation in 2011 and 2012 with the goal of exploring relationships between medication tradeoffs, medication non-adherence, and clinical outcomes. They determined that 17 percent of patients made medication tradeoffs, 10 percent reported an inability to purchase a medication due to cost, and 9 percent made the choice between buying medicine and buying food. Overall, 23 percent reported being non-adherent with medications.

According to Marina Serper, MD, "Individuals frequently have to make choices based on their economic situation. It is not surprising that they may choose to spend money on things other than medications, although you would expect this to be less prevalent in the posttransplant setting."

Patients with lower income, limited literacy, a higher number of chronic illnesses, and those taking more medications were more likely to have medication tradeoffs. Patients with tradeoffs were more than twice as likely to report non-adherence. Patients with tradeoffs had more hospitalizations after transplant than those who did not. The investigators suggested that the use of a tool similar to that used during the interviews conducted for this study would identify patients with cost-related barriers to proper medication adherence.

Dr. Serper added, "We need to be mindful of the effect of out-of-pocket costs on adherence and health outcomes in transplantation. Transplant centers routinely perform detailed psychosocial assessments prior to listing a patient for transplant, however, since financial situations may change, we may need to check in with patients more frequently after transplant, and intervene if needed."

Abstract title:
Medication Tradeoffs, Non-Adherence, and Clinical Outcomes among Liver Transplant Recipients

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in Washington, November 2-5, will bring together more than 9,000 researchers from 55 countries.

A pressroom will be available from November 1 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766.

Press releases and all abstracts are available online at www.aasld.org.

Media Contact: Gregory Bologna
703-299-9766
gbologna@aasld.org
Press Room: November 1 - 5, 2013
Walter E. Washington Convention Center, Washington, DC
Telephone: 202-249-4092

Researcher: Marina Serper, MD
Email: marina-serper@fsm.northwestern.edu
Phone: 215-718-4741

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.

SOURCE The American Association for the Study of Liver Diseases (AASLD)

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.